Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy

Yong Joon Lee, Jin Kyu Park, Jae Sun Uhm, Jong Yun Kim, huinam pak, Moon Hyoung Lee, Jung Hoon Sung, Boyoung Joung

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: The efficacy of oral anticoagulation therapy (OAT) has not been revealed in atrial fibrillation (AF) patients with newly diagnosed cancers. This study evaluated the thromboembolic and bleeding events in AF patients with malignancies according to OAT. Methods and results: In 2168 consecutive non-valvular AF patients with newly diagnosed malignancies, we analyzed the composite endpoints including major adverse cardiac events (MACEs) and major bleeding. Based on a propensity score matching, two groups with 690 matched pairs were created. Patient baseline characteristics were comparable between the matched groups. During a follow-up period of 3.9 ± 2.8 years, 72 (10%) and 65 (9%) patients had MACEs in the propensity score-matched OAT+ and OAT- groups, respectively (p = 0.461). There was no significant difference in the major bleeding (10% vs. 8%, p = 0.300) and composite endpoints (18% vs. 16%, p = 0.181) between OAT+ and OAT- patients. During the first year after the cancer diagnosis, 66 (48%) MACEs, 52 (41%) major bleedings, and 116 (49%) composite end points of all events occurred. The optimal international normalized ratio (2.0 to 3.0) level was achieved in only 85 (12%) patients. However, 1 year after cancer diagnosis, OAT+ patients with the target therapeutic range of ≥60% demonstrated better cumulative survival free of composite end point than OAT- patients (p = 0.026). Conclusion: During the first year after the cancer diagnosis, OAT did not improve the composite end point because of poor INR control caused by cancer treatment. However, after 1 year after diagnosis of cancer, optimal anticoagulation significantly reduced the composite end point.

Original languageEnglish
Pages (from-to)372-378
Number of pages7
JournalInternational Journal of Cardiology
Volume203
DOIs
Publication statusPublished - 2016 Jan 15

Fingerprint

Mouth Neoplasms
Hemorrhage
Atrial Fibrillation
Therapeutics
Neoplasms
Propensity Score
International Normalized Ratio
Group Psychotherapy
Research Design
Survival

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Lee, Yong Joon ; Park, Jin Kyu ; Uhm, Jae Sun ; Kim, Jong Yun ; pak, huinam ; Lee, Moon Hyoung ; Sung, Jung Hoon ; Joung, Boyoung. / Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. In: International Journal of Cardiology. 2016 ; Vol. 203. pp. 372-378.
@article{b3267e7f75ef4e13bcdbe1bce7a39d05,
title = "Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy",
abstract = "Background: The efficacy of oral anticoagulation therapy (OAT) has not been revealed in atrial fibrillation (AF) patients with newly diagnosed cancers. This study evaluated the thromboembolic and bleeding events in AF patients with malignancies according to OAT. Methods and results: In 2168 consecutive non-valvular AF patients with newly diagnosed malignancies, we analyzed the composite endpoints including major adverse cardiac events (MACEs) and major bleeding. Based on a propensity score matching, two groups with 690 matched pairs were created. Patient baseline characteristics were comparable between the matched groups. During a follow-up period of 3.9 ± 2.8 years, 72 (10{\%}) and 65 (9{\%}) patients had MACEs in the propensity score-matched OAT+ and OAT- groups, respectively (p = 0.461). There was no significant difference in the major bleeding (10{\%} vs. 8{\%}, p = 0.300) and composite endpoints (18{\%} vs. 16{\%}, p = 0.181) between OAT+ and OAT- patients. During the first year after the cancer diagnosis, 66 (48{\%}) MACEs, 52 (41{\%}) major bleedings, and 116 (49{\%}) composite end points of all events occurred. The optimal international normalized ratio (2.0 to 3.0) level was achieved in only 85 (12{\%}) patients. However, 1 year after cancer diagnosis, OAT+ patients with the target therapeutic range of ≥60{\%} demonstrated better cumulative survival free of composite end point than OAT- patients (p = 0.026). Conclusion: During the first year after the cancer diagnosis, OAT did not improve the composite end point because of poor INR control caused by cancer treatment. However, after 1 year after diagnosis of cancer, optimal anticoagulation significantly reduced the composite end point.",
author = "Lee, {Yong Joon} and Park, {Jin Kyu} and Uhm, {Jae Sun} and Kim, {Jong Yun} and huinam pak and Lee, {Moon Hyoung} and Sung, {Jung Hoon} and Boyoung Joung",
year = "2016",
month = "1",
day = "15",
doi = "10.1016/j.ijcard.2015.10.166",
language = "English",
volume = "203",
pages = "372--378",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. / Lee, Yong Joon; Park, Jin Kyu; Uhm, Jae Sun; Kim, Jong Yun; pak, huinam; Lee, Moon Hyoung; Sung, Jung Hoon; Joung, Boyoung.

In: International Journal of Cardiology, Vol. 203, 15.01.2016, p. 372-378.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy

AU - Lee, Yong Joon

AU - Park, Jin Kyu

AU - Uhm, Jae Sun

AU - Kim, Jong Yun

AU - pak, huinam

AU - Lee, Moon Hyoung

AU - Sung, Jung Hoon

AU - Joung, Boyoung

PY - 2016/1/15

Y1 - 2016/1/15

N2 - Background: The efficacy of oral anticoagulation therapy (OAT) has not been revealed in atrial fibrillation (AF) patients with newly diagnosed cancers. This study evaluated the thromboembolic and bleeding events in AF patients with malignancies according to OAT. Methods and results: In 2168 consecutive non-valvular AF patients with newly diagnosed malignancies, we analyzed the composite endpoints including major adverse cardiac events (MACEs) and major bleeding. Based on a propensity score matching, two groups with 690 matched pairs were created. Patient baseline characteristics were comparable between the matched groups. During a follow-up period of 3.9 ± 2.8 years, 72 (10%) and 65 (9%) patients had MACEs in the propensity score-matched OAT+ and OAT- groups, respectively (p = 0.461). There was no significant difference in the major bleeding (10% vs. 8%, p = 0.300) and composite endpoints (18% vs. 16%, p = 0.181) between OAT+ and OAT- patients. During the first year after the cancer diagnosis, 66 (48%) MACEs, 52 (41%) major bleedings, and 116 (49%) composite end points of all events occurred. The optimal international normalized ratio (2.0 to 3.0) level was achieved in only 85 (12%) patients. However, 1 year after cancer diagnosis, OAT+ patients with the target therapeutic range of ≥60% demonstrated better cumulative survival free of composite end point than OAT- patients (p = 0.026). Conclusion: During the first year after the cancer diagnosis, OAT did not improve the composite end point because of poor INR control caused by cancer treatment. However, after 1 year after diagnosis of cancer, optimal anticoagulation significantly reduced the composite end point.

AB - Background: The efficacy of oral anticoagulation therapy (OAT) has not been revealed in atrial fibrillation (AF) patients with newly diagnosed cancers. This study evaluated the thromboembolic and bleeding events in AF patients with malignancies according to OAT. Methods and results: In 2168 consecutive non-valvular AF patients with newly diagnosed malignancies, we analyzed the composite endpoints including major adverse cardiac events (MACEs) and major bleeding. Based on a propensity score matching, two groups with 690 matched pairs were created. Patient baseline characteristics were comparable between the matched groups. During a follow-up period of 3.9 ± 2.8 years, 72 (10%) and 65 (9%) patients had MACEs in the propensity score-matched OAT+ and OAT- groups, respectively (p = 0.461). There was no significant difference in the major bleeding (10% vs. 8%, p = 0.300) and composite endpoints (18% vs. 16%, p = 0.181) between OAT+ and OAT- patients. During the first year after the cancer diagnosis, 66 (48%) MACEs, 52 (41%) major bleedings, and 116 (49%) composite end points of all events occurred. The optimal international normalized ratio (2.0 to 3.0) level was achieved in only 85 (12%) patients. However, 1 year after cancer diagnosis, OAT+ patients with the target therapeutic range of ≥60% demonstrated better cumulative survival free of composite end point than OAT- patients (p = 0.026). Conclusion: During the first year after the cancer diagnosis, OAT did not improve the composite end point because of poor INR control caused by cancer treatment. However, after 1 year after diagnosis of cancer, optimal anticoagulation significantly reduced the composite end point.

UR - http://www.scopus.com/inward/record.url?scp=84952673549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952673549&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2015.10.166

DO - 10.1016/j.ijcard.2015.10.166

M3 - Article

C2 - 26539960

AN - SCOPUS:84952673549

VL - 203

SP - 372

EP - 378

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -